The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claims Analysis)

  • Lowest Price Guaranteed From USD 1,299

  • Published
    April 2022

  • Slides
    116

  • View Count
    335

Example Insights

CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Context-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Evolution-of-CAR-Constructs-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Historical-Trend-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Distribution-by-IP-Jurisdiction-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Prior-Art-Search-Expressions-thumb
CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Key-IP-Trends-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Key-Categories-of-Innovation-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Freedom-to-Operate-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Patent-Valuation-Analysis-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Patent-Claims-thumb
CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Key-Pockets-of-Innovation-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-White-Spaces-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Future-Developments-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Overview-of-Excel-Deliverable-thumb CAR-T-Cell-Therapies-Intellectual-Property-Landscape-Interactive-Excel-Deliverable-thumb

 

Overview

Cancer, one of the leading causes of death worldwide, claimed  close to 10 million lives annually Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. For instance, after multiple rounds of chemotherapy, a stem cell transplant, participating in two clinical trials of experimental anticancer interventions and targeted radiation therapy, Scott McIntyre was treated with a CAR T-cell therapy at the University of Chicago Medicine, in 2016. Till date, he is in complete remission from his diffuse large B-cell lymphoma (DLBCL). This highly specific and promising form of treatment that harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment across the world. CAR-T therapies have so far been evaluated and approved for several hematological malignancies; ABECMA® (relapsed or refractory multiple myeloma), BREYANZI® (relapsed or refractory large B-cell lymphoma), TECARTUS™ (relapsed or refractory B-cell precursor ALL), KYMRIAH™ (relapsed or refractory DLBCL and relapsed or refractory ALL), YESCARTA™ (DLBCL, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, and follicular lymphoma), are products involving the use of CAR-T cells, which have been approved by the US FDA.  

Presently, the success rate for CAR T-cell therapies is estimated to be around 30% to 40%, offering lasting remission without requiring any additional treatments. Cytokine release syndrome (CRS), a commonly reported side effect of the treatment, is typically observed within a few days to a couple of weeks after CAR T-cell infusion. In severe cases, patients with CRS may need to be transferred to intensive care and even require life-support machines to stay alive. However, over time, medical science has developed the necessary means to control / treat CRS. In addition, a successful CAR-T cell graft is known to cause certain rare types of infections, which are generally observed in severely immunodeficient patients. This is because the programmed, effector T-cells also eliminate normal immune cells, which are responsible for keeping infections at bay, in a healthy host. Other barriers to therapeutic success include inadequate anti-tumor activity (in certain cases), antigen escape, restricted trafficking, and limited tumor infiltration. As a result, there is a lot happening in terms of innovation related to this promising segment of cell-based therapies; medical researchers are developing targeted interventions for different indications and also exploring ways to make the therapy safer. It is also worth mentioning that a lot of capital has also been invested to support R&D activity in this burgeoning field of research. This report attempts to identify key trends that describe the pace and focus of innovation related to CAR-T cell therapies, and make key observations / inferences regarding the development of intellectual capital in this domain.

Scope of the Report

The “CAR-T Cell Therapies: Intellectual Property Landscape” report features an extensive study of the historical and current collection of granted patents, patent applications and affiliated documents associated with the upcoming suite of programmable, personalized anticancer therapies. The information in this report has been presented across two deliverables, namely a MS Excel sheet, featuring an interactive dashboard, and an MS PowerPoint presentation, summarizing the ongoing activity in this domain, and key insights drawn from the available data. The report features the following details:

  • Overall Intellectual Property Landscape

An in-depth review of the various patents and affiliated IP documents that have been published related to technologies and methods associated with the therapeutic applications of CAR-T cells, featuring key insights on historical and recent trends.

  • Popular / Relevant Prior Art Search Expressions

An examination of IP literature, including a shortlist of key words and phrases that have been used to describe innovations involving CAR-T cells that are indicated for the treatment of different types of cancers. The analysis also features historical usage trends of the aforementioned terms in IP filings, key affiliated terms (which can be used to further identify similar innovations), and other related details.

  • Patent Valuation Analysis

A competitive benchmarking and valuation analysis of the IP documents published in this field of innovation, taking into account important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in regional GDP).

  • Patentability and Freedom to Operate

A systematic approach to identify relevant areas of innovation by analyzing published IP documents, defining the uniqueness of patented / patent pending innovations, understanding the scope of patentability in this domain, and pinpointing jurisdictions where new and / or modified claims may be filed without infringing on existing IP. 

  • Analysis of Patent Applications

A detailed summary of the patent applications that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the intellectual capital in terms of area of innovation and intended applications, thereby, offering the means to understand key areas of research and identify innovation-specific IP filing trends.

  • Analysis of Granted Patents

An elaborate summary of the granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the intellectual capital in terms of area of innovation and intended applications; this offers the means to identify unique innovations that presently have marketing exclusivity, and the feasibility for innovators to enter into promising product markets. 

  • Pockets of Innovation and White Spaces

An insightful analysis of the various CPC symbols mentioned in published IP literature and their affiliated families, in order to identify historical and existing pockets of innovation (based on the functional area / industry described by the elaborate and systematic system of classifying IP); the analysis also features a discussion on the prevalent white spaces (based on CPC symbols) in this area of research.

  • Claims Analysis

One of the objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in granted, active patents in the dataset. Using a systematic segregation approach, we have analyzed trends associated with [A] the preamble, [B] type of patent (technology patent or method patent), [C] type of claim (open ended claim or closed ended claim) and [D] key elements of a claim (individual aspects of an innovation that are covered in a singular claim).

DELIVERABLE OUTLINES

Excel Deliverable
Sheet 1 features details regarding how the input data for this project was collated, including the search strings used to query a popular patent database (lens.org), and data segregation notes. 

Sheet 2 is a summary MS Excel dashboard, offering a detailed graphical perspective of the intellectual property landscape of CAR-T cell therapies. It includes pictorial representations of the [A] overall patent landscape, [B] key prior art search expressions, [C] trends related to patent applications (including insights on patentability and freedom to operate), [D] trends related to granted patents (including insights on patentability and freedom to operate), [E] key inferences from a proprietary claims analysis, [F] list of popular CPC symbols (featuring key pockets of innovation), [G] list of popular applicants (shortlisted based on number of published IP documents).
    
Sheet 3 is an elaborate tabular representation of the overall IP landscape, featuring information on the various patent application- and granted patent-related documents that have been published since 2000. 

Sheet 4 includes a tabular representation of key words and phrases that are used to describe CAR-T cell therapies.

Sheet 5 is a subset of sheet 3, featuring all the patent applications, covering intellectual capital related to CAR-T cell therapies.

Sheet 6 is a subset of sheet 3, featuring all the granted patents, covering intellectual capital related to CAR-T cell therapies. 

Sheet 7 is an insightful summary of key inferences from the independent claims mentioned in the granted, active patents in the dataset. We have used a systematic segregation approach to analyze trends associated with the preamble, type of patent (technology patent or method patent), type of claim (open ended claim or closed ended claim) and key elements of a claim (individual aspects of an innovation that are covered in a singular claim).

Sheet 8 provides insights related to some of the key applicants in this field of research, featuring company-specific details (such as year of establishment, and location of headquarters), and inputs on their respective IP publication trends. 
    
Sheet 9 features an analysis of the most popular (in terms of frequency of appearance in the dataset) CPC symbols and CPC families, related to CAR-T cell therapies.    

Sheet 10 is an appendix which includes pivot tables that drive the charts and interactive elements for the complete IP landscape, in sheet 2.

Sheet 11  is an appendix, featuring details related to the categorization done in the report, and important abbreviations used in reference to the data categories mentioned in the document. 

PowerPoint Deliverable
Chapter 1 briefly describes the need for better therapeutic options in the field of cancer treatment, and the key advantages of CAR-T cell therapies. It also features an overview of the intellectual property landscape related to this upcoming class of advanced therapy medicinal products. 

Chapter 2 and 3 feature brief (pictorial) summaries of the approach used for data collection and the key objectives of the study. 

Chapter 4 features an executive summary of the key insights generated from analyzing the intellectual property landscape of CAR-T cell therapies.

Chapter 5 provides a brief overview of T-cell therapies, the concept of chimeric antigen receptors and their applicability in personalized medicine. It also features a summary of the key events and milestones associated with the development of one of the most versatile classes of immunotherapies. The chapter lists the various US FDA approved CAR-T cell therapies and their key benefits and limitations. It concludes with a brief description of the likely future of this class of biological interventions. It is worth mentioning that the inputs featured in this chapter were validated based on the opinions of key experts involved in this segment of the biopharmaceutical industry. 
 
Chapter 6 includes a review of the various patents and IP documents that have been published describing various technologies and methods associated with CAR-T cell therapies, featuring key insights on historical and recent trends.

Chapter 7 features an insightful examination of IP literature, identifying key words and phrases that have been / are being used to describe CAR-T cell therapies. The chapter includes information on historical usage of the aforementioned expressions in IP filings, key affiliated terms (which can be used to further identify similar innovations), and other related trends.

Chapter 8 offers insights generated from a competitive benchmarking and valuation analysis of the IP documents related to CAR-T cell therapies, taking into account important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in regional GDP).

Chapter 9 provides a detailed summary of the patent applications that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the intellectual capital in terms of area of innovation and intended applications, thereby, offering the means to understand key areas of research and identify innovation-specific IP filing trends. Based on a systematic approach, the chapter highlights relevant areas of innovation from a deeper analysis of published IP documents, defining the uniqueness of patent pending innovations, understanding the scope of patentability in this domain, and pinpointing jurisdictions where new and / or modified claims may be filed without infringing on existing IP.

Chapter 10 is an elaborate summary of the granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis uses a segregation criterion, based on type of product / solution and intended applications; this offers the means to identify unique innovations that presently have marketing exclusivity and explore future opportunities to enter into promising product markets, once their patents expire. Based on a systematic approach, the chapter highlights relevant areas of innovation from a deeper analysis of published IP documents, defining the uniqueness of patented innovations, understanding the scope of patentability in this domain, and pinpointing jurisdictions where new and / or modified claims may be filed without infringing on existing IP.

Chapter 11 features profiles of some of the most popular applicant companies, which were shortlisted based on patent filing activity. Each profiles includes, a brief overview of the company, information on annual revenues (wherever available), details of its initiatives focused on the healthcare sector, names of key management team members and recent developments. 

Chapter 12 includes an insightful analysis of the various CPC symbols mentioned in the published IP literature and their affiliated families, in order to identify historical and existing pockets of innovation (based on the functional area / industry described by the elaborate and systematic system of classifying IP); the analysis also features a discussion on the prevalent white spaces (based on CPC symbols) in this area of research.

Chapter 13 concludes the report by providing insights on anticipated developments in this domain (from the perspective of eminent industry representatives of stakeholders in this domain), and trends that are likely to shape the future of the CAR-T cell therapies market. 

Chapter 14 is a set of appendices.

Contents

Table Of Contents

Excel Deliverable 
1. Research Notes

2. Summary Dashboard
A. Overall Intellectual Property Landscape
B Key Prior Art Search Expressions
C. Key Trends related to Patent Applications (featuring Patentability & Freedom to Operate)
D. Key Trends related to Granted Patents (featuring Patentability & Freedom to Operate)
E. Claims Analysis
F. Key CPC Symbols
G. Key Applicants

3. Overall Intellectual Property Landscape Dataset

4. Prior Art Search Expressions (Keyword Analysis)

5. Patent Applications Dataset

6. Granted Patents Dataset

7. Claims Analysis

8. Key Applicants Analysis

9. CPC Analysis

10. Appendix I: Pivot Tables

11. Appendix II: Country / Geography Codes

12. Appendix III: Innovation Categories

PowerPoint Deliverable 
1. Context

2. Project Approach

3. Project Objectives

4. Executive Summary

5. CAR-T cell therapies
5.1. Overview
5.2. History of Development
5.3. FDA Approved CAR-T cell therapies
5.4. Key Benefits and Limitations
5.5. Future Perspectives

6. Overall Intellectual Property Landscape
6.1. Overview
6.2. Analysis of Published IP Documents
6.3. Insights from Patent Applications
6.4. Insights from Granted Patents

7. Key Prior Art Search Expressions
7.1. Overview
7.2. Analysis of Prior Art Search Expressions

8. Intellectual Property Valuation Analysis
8.1. Valuation Overview
8.2. Analysis of Individual Value Ranks
8.2.1. Rank 1 IP Documents
8.2.2. Rank 2 IP Documents
8.2.3. Rank 3 IP Documents
8.2.4. Rank 4 IP Documents
8.2.5. Rank 5 IP Documents
8.3. Concluding Remarks

9. Analysis of Patent Applications
9.1. Overview
9.2. Relative Valuation of Patent Applications
9.3. Patentability & Freedom-to-Operate

10. Analysis of Granted Patents
10.1. Overview
10.2. Relative Valuation of Grated Patents
10.3. Patentability & Freedom-to-Operate
10.4. Analysis of Patent Claims

11. Key Applicants
11.1. Overview
11.2. Analysis of Key Applicants
11.2.1. University of Pennsylvania
11.2.2. Juno Therapeutics
11.2.3. Cellectis
11.2.4. University of California
11.2.5. bluebird bio
11.2.6. Memorial Sloan Kettering Cancer Center
11.2.7. Novartis
11.2.8. Baylor College of Medicine
11.2.9. Kite Pharma
11.2.10. University of Texas

12. Pockets of Innovation and White Spaces
12.1. Overview
12.2. Pockets of Innovation
12.3. White Spaces
12.4. Concluding Remarks

13. Future Outlook
14.1. Overview
14.2. Contemporary Sentiments & Expert Opinions
14.3. Anticipated Future Developments & Trends

14. Appendices

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. A2 Biotherapeutics
  2. AbClon
  3. Abion
  4. Accurus Biosciences
  5. Acerta Pharma
  6. Achelois Oncology
  7. Adaptimmune
  8. Adicet Bio
  9. Affyimmune Therapeutics
  10. Agency for Science, Technology and Research (A*STAR)
  11. Akeso Therapeutics
  12. Albert Einstein College of Medicine
  13. Aleta BioTherapeutics
  14. Allogene Therapeutics
  15. Almac
  16. Alpine Immune Sciences
  17. Altor Bioscience
  18. Ambrx
  19. American Gene Technologies
  20. Amgen
  21. Ampsource Biopharma Shanghai
  22. Apceth Biopharma
  23. Arcellx
  24. ARMO Biosciences
  25. Asclepius Technology Company Group (Suzhou)
  26. Asimov
  27. Atara Biotherapeutics
  28. Atossa Genetics
  29. Autolus Therapeutics
  30. Auxolytic
  31. Avacta Life Sciences
  32. Avectas
  33. Ayala Pharmaceuticals
  34. BCell Solutions
  35. Batu Biologics
  36. Baylor College of Medicine
  37. Beam Therapeutics
  38. Beijing Marino Biotechnology
  39. Bellicum Pharmaceuticals
  40. Ben-Gurion University of the Negev
  41. Benitec Biopharma
  42. Berkeley Lights
  43. BioMed Valley Discoveries
  44. BioNTech
  45. Biotheus
  46. bluebird bio
  47. Board of Regents - University of Texas System
  48. Boston 3T Biotechnologies
  49. Brigham and Women's Hospital
  50. Broad Institute
  51. Cafa Therapeutics
  52. California Institute for Biomedical Research
  53. California Institute of Technology
  54. Cancer Research Technology
  55. Cancer Targeting Systems
  56. Carina Biotech
  57. CARsgen Therapeutics
  58. Cartesian Therapeutics
  59. CARTEXELL
  60. Cartherics
  61. Case Western Reserve University
  62. Celgene
  63. Cell Design Labs
  64. Cell Medica
  65. Celldex Therapeutics
  66. Cellect
  67. Cellgentek
  68. Celllular Biomedicine Group
  69. Cellular Therapeutics
  70. Cellyan Therapeutics
  71. Celularity
  72. CERo Therapeutics
  73. Cerus Corporation
  74. Children's Healthcare of Atlanta
  75. Connecticut Children's Medical Center
  76. Chimera Bioengineering
  77. Chongqing Precision Biotech
  78. COARE Biotechnology
  79. Constant Therapeutics
  80. Council of the Queensland Institute of Medical Research
  81. Crescendo Biologics
  82. Crispr Therapeutics
  83. CTG Pharma
  84. Cue Biopharma
  85. CureGenetics
  86. Curocell
  87. Cynata Therapeutics
  88. CytoImmune Therapeutics
  89. Dana-Farber Cancer Institute
  90. DaRen
  91. Dartmouth College
  92. Diagnologix
  93. DINONA
  94. Dorian Therapeutics
  95. Dragonfly Therapeutics
  96. DRK-Blutspendedienst Baden-Württemberg – Hessen gGmbH
  97. East Tennessee State University
  98. EdiGene
  99. Editas Medicine
  100. ElevateBio
  101. Elstar Therapeutics
  102. Endocyte
  103. Enlivex Therapeutics
  104. Enochian Biopharma
  105. EpiVax
  106. Etubics Corporation
  107. EUCHLOE BIO
  108. Eureka Therapeutics
  109. Eutilex
  110. Exuma Biotechnology
  111. F1 Oncology
  112. Fate Therapeutics
  113. Five Prime Therapeutics
  114. Flagship Pioneering
  115. FloDesign Sonics
  116. San Raffaele Hospital
  117. Tettamanti Foundation
  118. Telethon Foundation
  119. Forevertek Biotechnology
  120. Fortis Therapeutics
  121. Forty Seven
  122. Fujifilm Cellular Dynamics
  123. Josep Carreras Leukemia Research Institute
  124. Fundamenta Therapeutics
  125. Wuling(Fuzhou) Biotechnology
  126. GammaDelta Therapeutics
  127. GAVISH - GALILEE BIO APPLICATIONS
  128. GE Healthcare Systems
  129. GEMoaB Monoclonals
  130. Genentech
  131. Geneuin-Tech
  132. GigaMune
  133. GlaxoSmithKline
  134. Good T cells
  135. GPB Scientific
  136. Gracell Biotechnologies
  137. Green Cross LabCell
  138. Gritstone Oncology
  139. TCRCure Biopharma
  140. Guangzhou Bio-gene Technology
  141. Guangzhou Institute of Biomedicine and Health
  142. Moffitt Cancer Center
  143. HaemaLogiX
  144. Hangzhou ConVerd
  145. U-Cell Therapeutics
  146. Harpoon Therapeutics
  147. Harvard College
  148. Health Research
  149. Hebei Senlang Biotechnology
  150. Heinrich Heine University Düsseldorf
  151. Helix BioPharma
  152. Helmholtz Zentrum München
  153. Henry M. Jackson Foundation for the Advancement of Military Medicine
  154. HRYZ Biotech
  155. Hunan HuiRui Pharmaceutical
  156. Humanigen
  157. Igm Biosciences
  158. Imel Biotherapeutics
  159. Immatics Biotechnologies
  160. Immatics Us
  161. IMMPACT
  162. Immune Design
  163. Immungene
  164. Immunocore
  165. Immunomedics
  166. Immunotech Biopharm
  167. Imperial College of Science, Technology and Medicine
  168. IN8bio
  169. Indian Institute of Technology Bombay
  170. Inhibrx
  171. Innovative Cellular Therapeutics
  172. Inscripta
  173. Instil Bio
  174. Cancer Research Institute
  175. Intellia Therapeutics
  176. Intima Bioscience
  177. Intrexon
  178. Io Therapeutics
  179. Iovance Biotherapeutics
  180. Janssen Biotech
  181. Javelin Oncology
  182. Jazz Pharmaceuticals
  183. Johannes Gutenberg University Mainz
  184. JOHNPRO BIOTECH
  185. JSR Corporation
  186. Cellectis
  187. Juno Therapeutics
  188. JUNTEN BIO
  189. Jura Bio
  190. Kangstem Biotech
  191. King's College London
  192. Kite Pharma
  193. Hauner'sches Children's Hospital
  194. Korea Advanced Institute of Science and Technology
  195. Korea Reseach Institute of Bioscience & BioTechnology
  196. KSQ Therapeutics
  197. Kumquat Biosciences
  198. Kyoto Prefectural University
  199. La Jolla Institute for Immunology
  200. Leucid Bio
  201. Life Technologies
  202. LionTCR
  203. Lonza Cologne
  204. Lonza
  205. Lorantis
  206. Ludwig Institute for Cancer Research
  207. Ludwig Maximilian University of Munich
  208. Lycera
  209. Mabimmune
  210. MabSpace Biosciences
  211. MIT - Massachusetts Institute of Technology
  212. Maxcyte
  213. Mayo Foundation For Medical Education
  214. Med Manor Organics
  215. MEDICAL & BIOLOGICAL LABORATORIES
  216. Medical College of Wisconsin
  217. Medicenna Therapeutics
  218. Medigene
  219. Medimmune
  220. Medinet
  221. Medisix Therapeutics
  222. MicroCures
  223. Millennium Pharmaceuticals
  224. Miltenyi Biotec
  225. Minerva Biotechnologies
  226. Mingsight Pharmaceuticals
  227. Modernatx
  228. MOGAM Institute for Biomedical Research
  229. Monarch Biosciences
  230. MUSC Foundation for Research Development
  231. Mustang Bio
  232. MVZ Prof. Dr. med. Niendorf Pathologie Hamburg-West
  233. BioHeng
  234. Nanjing Kaedi Biotech
  235. Nanjing Legend Biotech
  236. NanoTomer
  237. Nantbio
  238. Nantcell
  239. Nantkwest
  240. The National Institute for Biotechnology in the Negev
  241. Chungbuk National University
  242. Nagoya University
  243. NUS - National University of Singapore
  244. Shiga University of Medical Science
  245. NDSU Research Foundation
  246. Nectintx
  247. NeoImmuneTech
  248. Neon Therapeutics
  249. NexImmune
  250. Nkarta
  251. Noile-Immune Biotech
  252. Novartis
  253. Novoscope Ip
  254. Oaiscell Biotechnologies
  255. Obsidian Therapeutics
  256. Innovation Ohio
  257. OncoHost
  258. Oncoimmune
  259. Oncorus
  260. OncoTab
  261. OncoTherapy Science
  262. ONK Therapeutics
  263. Oncimmune
  264. Orig3n
  265. OxfordBiomedica
  266. Pact Pharma
  267. Pharos Vaccine
  268. Pieris Pharmaceuticals
  269. Poseida Therapeutics
  270. Precision BioSciences
  271. Precision NanoSystems
  272. Precigen
  273. Promab Biotechnologies
  274. Protelica
  275. Provincial Health Services Authority
  276. PsiOxus Therapeutics
  277. Purdue Research Foundation
  278. QT Holding
  279. Qu Biologics
  280. Quell Therapeutics
  281. Rambam MedTech
  282. Refuge Biotech
  283. Regen BioPharma
  284. Regeneron Pharmaceuticals
  285. Research Institute at Nationwide Children's Hospital
  286. Rinat Neuroscience
  287. Shanghai JiaoTong University Ruijing Hospital
  288. Russell Biotech
  289. Sangamo Therapeutics
  290. AZABU UNIVERSITY
  291. Scripps Research
  292. Senti Biosciences
  293. Shanghai Cell Therapy Group
  294. Genbase-Shanghai Genbase Biotechnology
  295. unicar-therapy
  296. Shattuck Labs
  297. Shenzhen Pregene Biopharma
  298. Memorial Sloan Kettering Cancer Center
  299. Sorrento Therapeutics
  300. SpringWorks Therapeutics
  301. SQZ Biotech
  302. St. Jude Children's Research Hospital
  303. Netherlands Cancer Institute
  304. Sunshine Lake Pharma
  305. Syndax Pharmaceuticals
  306. SYNIMMUNE
  307. Syno Minicircle Biotechnology
  308. Takara Bio
  309. Takeda
  310. Tayu Huaxia Biotech Medical Group
  311. TC BioPharm
  312. TCR² Therapeutics
  313. TCRCure
  314. Technion Research & Development Foundation
  315. Technical University of Munich
  316. tella
  317. Temple University-of The Commonwealth System of Higher Education
  318. Terumo Global
  319. Tessa Therapeutics
  320. The Texas A&M University System
  321. Fourth Military Medical University
  322. Massachusetts General Hospital
  323. Nemours Foundation
  324. Trustees of the University of Pennsylvania
  325. University of Notre Dame
  326. TheryCell
  327. Thyas
  328. Timmune Biotech
  329. Torque Therapeutics
  330. Tri-Institutional Therapeutics Discovery Institute
  331. Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz
  332. University of Alabama at Birmingham
  333. UCL Business
  334. Umoja Biopharma
  335. Aix-Marseille University
  336. University of Alberta
  337. University of Arizona
  338. Bar-Ilan University
  339. University of Basel
  340. Charite University Hospital
  341. University of Birmingham
  342. University of Bonn
  343. Boston University
  344. Braunschweig University of Technology
  345. University of British Columbia
  346. Vrije Universiteit Brussel
  347. University of California
  348. University of Chicago
  349. University of Colorado Board of Regents
  350. Columbia University
  351. Cornell University
  352. Dankook University
  353. University of Évry Val d'Essonne
  354. Duke University
  355. Emory University
  356. University of Florida
  357. University of Freiburg
  358. Fudan University
  359. University of Geneva
  360. Ghent University
  361. The George Washington University
  362. University Health Network (UHN)
  363. University of Houston System
  364. University of Illinois Urbana-Champaign
  365. Indiana University Research & Technology
  366. University of Iowa Research Foundation
  367. Thomas Jefferson University
  368. Johns Hopkins University
  369. University of Kansas
  370. Keio University
  371. University of Cologne
  372. Kyoto University
  373. Stanford University
  374. Loyola University
  375. Autonomous University of Madrid
  376. University of Maryland, College Park
  377. University of Massachusetts
  378. China Medical University
  379. University of Miami
  380. Regents of the University of Michigan
  381. Mie University
  382. University of Minnesota
  383. Monash University
  384. Université de Montréal
  385. University of Nantes
  386. National University Corporation Kochi University
  387. University of Nebraska–Lincoln
  388. The University of North Carolina at Chapel Hill
  389. University of North Carolina at Charlotte
  390. Northwestern University
  391. University of Nottingham
  392. University of Lausanne
  393. University of Southern Denmark
  394. University of Oslo
  395. Oxford University Innovation
  396. University of Paris
  397. University of Pennsylvania
  398. University of Pittsburgh
  399. Princeton University
  400. University of Regensburg
  401. Rice University
  402. University of Rouen
  403. Rutgers University
  404. Sapporo Medical University
  405. Seoul National University
  406. Shinshu University
  407. SiChuan University
  408. University of Southampton
  409. University of Southern California
  410. University of Strasbourg
  411. University of Tennessee
  412. University of Texas at Austin
  413. University of Toledo
  414. Tsinghua University
  415. University of Tübingen
  416. Vanderbilt University
  417. University of Washington
  418. Wayne State University
  419. University of Natural Resources and Applied Life Sciences
  420. Julius Maximilian University of Würzburg
  421. Yale University
  422. Yamaguchi University
  423. Zhejiang University
  424. University of Cologne
  425. University of Verona
  426. Laval University
  427. University of Houston System
  428. UNUM Therapeutics
  429. University of Victoria
  430. UWELL BioPharma
  431. Var2 Pharmaceuticals
  432. Verastem Oncology
  433. Blood Research Institute - Versiti
  434. ViroMed
  435. Vivia Biotech
  436. Vor Biopharma.
  437. Vycellix
  438. Western Sydney Local Health District
  439. West China hospital, sichuan university
  440. University of Münster
  441. Whitehead Institute
  442. WindMIL Therapeutics
  443. Wisconsin Alumni Research Foundation
  444. Wilson Wolf Manufacturing
  445. Wugen
  446. Wuhan Bio-Raid Biotechnology Co. Ltd.
  447. WuXi Biologics
  448. Y-mAbs Therapeutics, Inc.
  449. Yeda Research & Development Co Ltd
  450. Yissum Technology Transfer Company of the Hebrew University
  451. Shanghai Yizun Pharmaceutical Technology
  452. Yufan Biotechnologies
  453. zPREDICTA
  454. Zymeworks

PRICING DETAILS

USD 1,299

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com